Source-grounded facts extracted from Aardvark Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Aardvark Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $91.2 million, net income net loss of $21.6 million.
“Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark”
Material Agreements
Aardvark Therapeutics, Inc. entered into Equity Distribution Agreement with Piper Sandler & Co. valued at up to $150,000,000 (effective 2026-03-23).
“On March 23, 2026, Aardvark Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co., as sales agent (the “Agent”), pursuant to which the Company may, from time to time, in its sole discretion, offer and sell through or to the Agent, shares (“Shares”) of its common stock, par value $0.00001 per share.”
Earnings Releases
Aardvark Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 23, 2026, Aardvark Therapeutics, Inc. issued a press release reporting its financial results for the quarter and full year ended December 31, 2025, and providing pipeline and business updates.”
Governance Changes
Aardvark Therapeutics, Inc.: Amended and restated bylaws effective immediately prior to IPO, establishing procedures for stockholder proposals and director nominations, modifying indemnification provisions, and conforming to amended certificate (effective 2025-02-14).
“the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders, became effective as of immediately prior to the completion of the IPO on February 14, 2025”
Governance Changes
Aardvark Therapeutics, Inc.: Amended and restated certificate of incorporation in connection with IPO, including increasing authorized common stock to 490M shares, eliminating preferred stock references, authorizing 10M undesignated preferred shares, requiring two-thirds vote for director removal, establishing classified board, (effective 2025-02-14).
“on February 14, 2025, the Company filed its fourth amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.